Real World European Investigation of Safety and Clinical Efficacy of the EVOQUE System (TRISCEND III EU)
This study, called TRISCEND III EU, is about a new treatment for a heart problem where one of the heart's valves, called the tricuspid valve, isn't closing properly and leaks. This is known as tricuspid valve regurgitation. The treatment involves a special device called the Edwards EVOQUE system, which is put into the heart using a small tube, rather than open heart surgery. Doctors want to see how well this system works and how safe it is for people in real-life situations. Up to 500 patients across Europe will take part. They will be checked regularly for five years after having the treatment. The aim is to understand more about this treatment and help people with this heart condition.
At a glance
What is this study about?
This study is called TRISCEND III EU and it's looking at a new way to treat a common heart problem. Inside your heart, there are four valves that act like one-way doors, making sure blood flows in the right direction. One of these is the tricuspid valve. Sometimes, this valve doesn't close properly, causing blood to leak backward. This is called tricuspid valve regurgitation, and it can make your heart work harder and lead to symptoms like breathlessness and tiredness.
For some people, traditional open-heart surgery to fix or replace this valve might be too risky. This study is testing a new, less invasive treatment called the Edwards EVOQUE system. Instead of open surgery, doctors can guide a small, flexible tube (a catheter) through a blood vessel to your heart. This tube carries the new EVOQUE valve, which is then placed inside your old, leaky valve to help it work better. This type of procedure is known as a transcatheter tricuspid valve replacement.
The main goal of this study is to gather information on how well the EVOQUE system works and how safe it is for people in everyday medical practice. It's a 'real-world' study, meaning it looks at how the device performs in patients under normal care. Doctors hope to learn if this new treatment can help improve the health and quality of life for people with this specific heart valve problem.
Key takeaways
- This study is testing a new, less invasive heart valve treatment.
- It's for people with a leaky tricuspid heart valve.
- The treatment involves a device called the EVOQUE system, placed using a catheter.
- Participants will be followed for five years after their procedure.
- The aim is to understand how safe and effective this treatment is in real life.
- You can withdraw from the study at any time without affecting your care.
Who may be eligible?
To be considered for this study, your heart care team at the local hospital would first need to decide that the EVOQUE treatment is the right option for you, based on its current guidelines for use. It's important that you understand and agree to attend all the planned follow-up appointments, which will happen over several years.
You would also need to provide your written consent, which means you've had all the information explained to you, you understand what taking part involves, and you agree to participate voluntarily. This consent form gives doctors permission to use your health information for the study.
You wouldn't be able to join if you're already taking part in another similar study that involves a new medical treatment, drug, or device and hasn't yet finished collecting its main results. Also, the study can't include people who are considered 'vulnerable populations,' which generally means individuals who might not be able to fully understand or freely agree to participate, such as very young children or those with certain mental health conditions.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Has my heart doctor said the EVOQUE treatment might be right for me?
- Am I willing and able to attend all the follow-up appointments for five years?
- Am I happy to sign a consent form after understanding everything about the study?
- Am I NOT currently in another study testing a new medical treatment or device?
- Am I an adult who can make my own decisions about my healthcare?
What does participation involve?
If you decide to take part in this study, you would first have the EVOQUE system fitted. After the procedure, your health would be checked at several points. You would have appointments before the procedure, when you leave the hospital (or within 7 days), and then again after 30 days. Following this, you would have annual check-ups for five years.
These check-ups might involve various tests, such as heart scans or blood tests, and discussions with your doctor or nurse to see how you are feeling and how the treatment is working. The study expects to enroll new patients over about 2 to 4 years, and then everyone will be followed for up to 5 years after their procedure. This means your total involvement, from the time you receive the treatment to your last check-up, could be around five years.
Potential risks and benefits
Locations (23)
- Zentralklinik Bad Berka GmbHVerified postcodeBad Berka, Germany· Recruiting
- Kerckhoff-Klinik GmbH Bad NauheimVerified postcodeBad Nauheim, Germany· Recruiting
- Rhoen-Klinikum Campus - Bad NeustadtVerified postcodeBad Neustadt an der Saale, Germany· Recruiting
- Herz-und Diabeteszentrum NRWVerified postcodeBad Oeynhausen, Germany· Recruiting
- Deutsches Herzzentrum der Charité (DHZC)Verified postcodeBerlin, Germany· Recruiting
- Herzzentrum Universitaet BonnVerified postcodeBonn, Germany· Recruiting
- St. Johannes Hospital DortmundVerified postcodeDortmund, Germany· Recruiting
- Universitatsklinik EssenVerified postcodeEssen, Germany· Recruiting
- Asklepios Klinik St Georg HamburgVerified postcodeHamburg, Germany· Recruiting
- Universitaetsklinikum Schleswig Holstein Campus KielVerified postcodeKiel, Germany· Recruiting
- Leipzig HerzzentrumVerified postcodeLeipzig, Germany· Recruiting
- Universitaetsklinikum Schleswig Holstein Campus LubeckVerified postcodeLübeck, Germany· Recruiting
Common questions
What is 'tricuspid valve regurgitation'?
It's when one of the heart's valves, called the tricuspid valve, doesn't close properly, allowing blood to leak backwards in the heart.
What is the EVOQUE system?
It's a new device designed to replace a leaky tricuspid valve. It's put into the heart using a small tube (catheter) rather than open surgery.
How long will I be followed if I join?
After your procedure, you'll have check-ups for five years to see how the treatment is working.
Can I leave the study once I've started?
Yes, you can choose to stop participating in the study at any time, and this will not affect your regular medical care.
What does 'real-world study' mean?
It means the study is looking at how the treatment works for patients in typical healthcare settings, as part of their routine care.
How to find out more
TMTT Clinical
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.